PASSAGE BIO, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
PASSAGE BIO, INC. (PASG) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$1.09 million for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-09-03
- PASSAGE BIO, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$328.00K, a 515.19% decline year-over-year.
- PASSAGE BIO, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$758.00K.
- PASSAGE BIO, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $652.00K.
- PASSAGE BIO, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$72.00K.
- PASSAGE BIO, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $659.00K.
- PASSAGE BIO, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$7.34M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$328.00K derived: S-4/A 6 month − S-4 3 month · filed 2026-09-03 | -$1.09M S-4/A · filed 2026-09-03 | -$434.00K derived: sum of 3 quarters · filed 2026-09-03 | -$506.00K derived: sum of 4 quarters · filed 2026-09-03 |
| 2026-03-31 | -$758.00K S-4 · filed 2026-07-21 | -$106.00K derived: sum of 2 quarters · filed 2026-09-03 | -$178.00K derived: sum of 3 quarters · filed 2026-09-03 | -$99.00K derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-12-31 | $652.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $580.00K derived: sum of 2 quarters · filed 2026-09-03 | $659.00K derived: sum of 3 quarters · filed 2026-09-03 | -$2.05M S-4/A · filed 2026-09-03 |
| 2025-09-30 | -$72.00K derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-10 | $7.00K derived: sum of 2 quarters · filed 2026-09-03 | -$2.71M 10-Q · filed 2025-11-10 | -$2.73M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-06-30 | $79.00K derived: S-4/A 6 month − S-4 3 month · filed 2026-09-03 | -$2.63M S-4/A · filed 2026-09-03 | -$2.66M derived: sum of 3 quarters · filed 2026-09-03 | -$3.99M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-03-31 | -$2.71M S-4 · filed 2026-07-21 | -$2.73M derived: sum of 2 quarters · filed 2026-09-03 | -$4.07M derived: sum of 3 quarters · filed 2026-09-03 | -$3.49M derived: sum of 4 quarters · filed 2026-09-03 |
| 2024-12-31 | -$22.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | -$1.36M derived: sum of 2 quarters · filed 2026-09-03 | -$776.00K derived: sum of 3 quarters · filed 2026-09-03 | -$4.96M S-4/A · filed 2026-09-03 |
| 2024-09-30 | -$1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$754.00K derived: sum of 2 quarters · filed 2025-11-10 | -$4.94M 10-Q · filed 2025-11-10 | -$6.98M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $580.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$3.61M 10-Q · filed 2025-08-12 | -$5.65M derived: sum of 3 quarters · filed 2025-08-12 | -$5.10M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$4.19M 10-Q · filed 2025-05-13 | -$6.23M derived: sum of 2 quarters · filed 2025-05-13 | -$5.68M derived: sum of 3 quarters · filed 2025-05-13 | -$5.39M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$1.49M derived: sum of 2 quarters · filed 2025-03-04 | -$1.21M derived: sum of 3 quarters · filed 2025-03-04 | $659.00K 10-K · filed 2025-03-04 |
| 2023-09-30 | $552.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $835.00K derived: sum of 2 quarters · filed 2024-11-13 | $2.70M 10-Q · filed 2024-11-13 | $425.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $283.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.15M 10-Q · filed 2024-08-08 | -$127.00K derived: sum of 3 quarters · filed 2024-08-08 | -$1.47M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.87M 10-Q · filed 2024-05-14 | -$410.00K derived: sum of 2 quarters · filed 2024-05-14 | -$1.75M derived: sum of 3 quarters · filed 2024-05-14 | -$648.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | -$3.62M derived: sum of 2 quarters · filed 2024-03-04 | -$2.52M derived: sum of 3 quarters · filed 2024-03-04 | -$7.34M 10-K · filed 2024-03-04 |
| 2022-09-30 | -$1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$238.00K derived: sum of 2 quarters · filed 2023-11-13 | -$5.06M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$3.72M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | -$4.82M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |